Treating schizophrenia during menopause

  title={Treating schizophrenia during menopause},
  author={Amnon Brzezinski and Noa A. Brzezinski-sinai and Mary V. Seeman},
Objective: The aim of this review is to examine three questions: What are the risks and benefits of treating women with schizophrenia with hormone therapy (HT) at menopause? Should the antipsychotic regimen be changed at menopause? Do early- and late-onset women with schizophrenia respond differently to HT at menopause? Methods: MEDLINE databases for the years 1990 to 2016 were searched using the following interactive terms: schizophrenia, gender, menopause, estrogen, and hormones. The selected… 

The Effect of Menopause on Antipsychotic Response

The evidence suggests that symptom level in women with schizophrenia rises after menopause for many reasons beyond hormones but, importantly, there is an estrogen-dependent loss of efficacy related to antipsychotic treatment.

Peri- and Post-Menopausal Women with Schizophrenia and Related Disorders Are a Population with Specific Needs: A Narrative Review of Current Theories

Antipsychotic dose adjustment at menopause is recommended for schizophrenia and raloxifene may play an important role in permitting dose reduction and lessening adverse effects.

Schizophrenia Psychosis in Women

Clinical recommendations need to consider clinical and role differences that exist between men and women and make appropriate correction for age and reproductive status in the treatment of psychosis, specifically schizophrenia.

Schizophrenia and Sex Hormones: What Is the Link?

The current knowledge on the link between blood levels of sex-hormones in women during the various stages of the female reproductive life and the course of schizophrenia is presented and the clinical approach to women with schizophrenia at these different stages is attempted.

Use of psychotropic medication in women with psychotic disorders at menopause and beyond

It is concluded that antipsychotic drugs with a wider range of action and with fewer side effects are urgently needed and older women's needs must be assessed through a comprehensive history and review of systems and physical and mental examination.

Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia?

An integrated and synthesized overview of the current state of knowledge regarding sex-specific aspects in schizophrenia and how this topic may be adapted in the development of CPGs is given.

Men and women respond differently to antipsychotic drugs

  • M. Seeman
  • Psychology, Medicine
  • 2020

Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.

HT is an effective treatment for bothersome menopausal vasomotor symptoms, genitourinary syndrome, and prevention of osteoporotic fractures and can improve bothersome symptoms, all the while conferring offset benefits such as cardiovascular risk reduction and a reduction in bone fracture risk.

Do Sex/Gender and Menopause Influence the Psychopathology and Comorbidity Observed in Delusional Disorders?

It was found that erotomania was more prevalent in women than in men, and especially in women with premenopausal onset, and levels of female hormones, influence symptom expression in women and mediate the expression of psychiatric comorbidities.

Women and schizophrenia: planning for the future

It is concluded that gender differences influence the effectiveness of various treatments and need to be taken into account when planning comprehensive care services for individuals with schizophrenia.



Antipsychotic Response Worsens With Postmenopausal Duration in Women With Schizophrenia

Time since menopause was significantly negatively associated with antipsychotic response in postmenopausal schizophrenic women, suggesting a decline in antipsychotics response after menophere, and smoking and cumulative estrogen exposures were associated with improvement in negative symptoms.

Treating schizophrenia at the time of menopause.

Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.

Raloxifene as an adjuvant treatment in postmenopausal women with schizophrenia who exhibit prominent negative symptoms appears to be useful in improving negative, positive, and general psychopathological symptoms.

Managing the menopause: An update.

Hormones and schizophrenia

The literature reviewed here suggests that hormones such as oestrogen could be a viable option for schizophrenia, and it is hoped that, with further research and larger trials, the oestrogens protection hypothesis can be translated into effective clinical practice.

Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia

The results of this study suggest that short-term HRT is an effective adjuvant modality for improving cognitive function in women of childbearing age with chronic schizophrenia.